




## Division of Medical Services Pharmacy Program

P.O. Box 1437, Slot S415 · Little Rock, AR 72203-1437  
501-683-4120 · Fax: 501-683-4124 or 1-800-424-5851



### ARKANSAS MEDICAID DUR BOARD QUARTERLY DRUG UPDATE

**April 20, 2022 8:30 A.M. – 12:30 P.M.**

DEPARTMENT OF HUMAN SERVICES

Virtual meeting only

Please click the link below to join the webinar:

<https://us02web.zoom.us/j/82974494973?pwd=cU93SzNtOERTeFR0RFZpZWdqR1BiQT09>

**\*\*TENTATIVE AGENDA IS SUBJECT TO CHANGE\*\***

#### I. OUTSIDE SPEAKERS

*DUR Board Bylaws, Section 7.02, allow **Outside speakers** at the meeting--* Outside speakers with clinical or scientific credentials or patient experience pertinent to a product or topic that is posted on the upcoming DUR Board meeting agenda may request to speak on that product or topic. Requests to speak at the DUR Board meeting must be made in writing to the DUR Chairperson at least two (2) weeks before the DUR Board meeting date, and should include:

- (1) The speaker's name, title, relevant credentials, and organization;
- (2) Contact information for the speaker including address, telephone number, and email;
- (3) The agenda item(s) which the speaker intends to address;
- (4) Prepared comments; and
- (5) An electronic copy of any presentation materials the speaker intends to use.

This information shall be included in information sent to Board members two (2) weeks prior to the Board meeting. Presentations or public comments given at the DUR Board meeting are limited to a total of six (6) minutes per drug, which may be shared by multiple speakers. This time limit does not include responses to any questions raised by DUR Board members during the course of the meeting.

A copy of the proposed criteria for the specific agenda item on which an individual request to speak may be requested from the Chairperson three (3) weeks prior to the DUR Board meeting. The information will be in draft form and may be changed by the DUR Board prior to being finalized. As such, the draft criteria should not be shared with clinicians or patients.

#### II. UNFINISHED / OLD BUSINESS AND GENERAL ORDERS / AND PROPOSALS TO REVISE PREVIOUS CRITERIA

- A. ANNOUNCEMENTS
- B. APPROVAL OF THE MINUTES FROM THE PREVIOUS MEETING.
- C. UPDATE ON SYSTEM EDITS, IMPLEMENTATIONS, OR FOLLOW-UP ITEMS.
  - 1) Follow-up items from January 19, 2022 DUR Board Quarterly Drug Update: None
  - 2) Implementation information from January 19, 2022 DUR Board Quarterly Drug Update and February 9, 2022 Preferred Drug List (PDL) Drug Review Update
- D. PROPOSED CHANGES TO EXISTING CRITERIA and EDITS, INCLUDING POINT OF SALE (POS) CRITERIA, MANUAL REVIEW PA CRITERIA, OR CLAIM EDITS:
  - 1) Nausea and vomiting in pregnancy

#### III. NEW BUSINESS

- A. PROPOSED NEW CLINICAL POINT OF SALE CRITERIA WITH OR WITHOUT ADDITIONAL CLAIM EDITS: None
- B. MANUAL REVIEW PROPOSED CRITERIA WITH OR WITHOUT ADDITIONAL CLAIM EDITS:
  - 1) Livmarli™ (maralixibat)
  - 2) Livtency™ (maribavir)
  - 3) Tarpeyo™ (budesonide)
  - 4) Apretude (cabotegravir)
  - 5) Leqvio® (inclisiran)
  - 6) Recorlev® (levoketoconazole)
  - 7) Besremi® (ropeginterferon alfa-2b)
  - 8) Vonjo™ (pacritinib)—if rebateable at the time of DUR Board meeting
  - 9) Pyrukynd® (mitapivat)
  - 10) Oxervate™ (cenegermin-bkbj)
- C. PROPOSED NEW CLAIM EDITS (QUANTITY, DAILY DOSE, ACCUMULATION, GENDER, AGE): None
- D. ProDUR REPORT UPDATE
- E. RDUR REPORT UPDATE

<https://humanservices.arkansas.gov/>

Protecting the vulnerable, fostering independence and promoting better health